News|Videos|February 24, 2023
Unmet Needs and Future Perspectives in the Treatment of CLL
The panel shares some final thoughts on unmet needs and the future of CLL treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?
2
Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer
3
FDA OKs Pirtobrutinib in Frontline CLL/SLL
4
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
5